Compatible vial container closure system (CCS) components in combination with a proper
capping process are crucial to ensuring reliable performance, maintaining container closure …

Capping completes the closure of parenteral drug products in the final packaging container
and is critical in maintaining an integral seal to ensure product quality. Residual seal force …

Container closure integrity (CCI) is one of the requirements for a sterile packaging system.
For vial-based systems, the capping process is a critical step in creating and ensuring an …

The vial capping process is a critical unit operation during drug product manufacturing, as it
could possibly generate cosmetic defects or even affect container closure integrity. Yet there …

Capping equipment used in good manufacturing practice manufacturing features different
designs and a variety of adjustable process parameters. The overall capping result is a …

Capping equipment used in good manufacturing practice (GMP) manufacturing feature
different designs and a variety of adjustable process parameters. The overall capping result …

Container closure integrity (CCI) testing, along with other engineering and administrative
controls, must be incorporated into a holistic approach to ensure overall integrity of a …

Frozen-state storage and cold-chain transport are key operations in the development and
commercialization of biopharmaceuticals. Today, several marketed drug products are stored …

A vial-capping process for lyophilization stopper configurations was previously quantified
using residual seal force (RSF). A correlation between RSF and container closure integrity …

Parenteral drug products are protected by appropriate primary packaging to protect against
environmental factors, including potential microbial contamination during shelf life duration …